Cybin is trading 5.24% up at $10.72 in pre-market on October 26, with no clear company-specific catalyst identified.

  • The provided market snapshot is broadly positive, but it does not establish that Cybin is moving with the wider market.
  • Recent coverage expects the HLP003 Phase 3 APPROACH readout in Q4 2026; that earlier update does not explain this morning’s gain.